Immunocore Appoints New CMO, Elects Director

TL;DR

Immunocore beefs up leadership with new CMO and board member.

AI Summary

Immunocore Holdings plc announced on May 28, 2024, the appointment of Dr. Joanna Horobin as Chief Medical Officer and the election of Dr. Richard J. Davies to its Board of Directors. The company also reported on its financial statements and exhibits, indicating ongoing operational activities and potential strategic developments.

Why It Matters

The appointment of a new Chief Medical Officer and a new board member can signal strategic shifts in the company's R&D focus and governance, potentially impacting future drug development and business strategy.

Risk Assessment

Risk Level: low — This filing primarily concerns executive appointments and standard financial reporting, with no immediate indication of significant financial distress or major strategic risks.

Key Players & Entities

• Immunocore Holdings plc (company) — Registrant
• Dr. Joanna Horobin (person) — Appointed Chief Medical Officer
• Dr. Richard J. Davies (person) — Elected to Board of Directors

FAQ

Key Financial Figures

• $325,790 — n option grant to purchase an estimated $325,790 of the Company's ordinary shares, with
• $5,202,000 — Brothers Life Sciences, L.P. purchased $5,202,000 and $54,798,000 in principal amount of
• $54,798,000 — Sciences, L.P. purchased $5,202,000 and $54,798,000 in principal amount of the Notes, respe
• $60,000,000 — nt of the Notes, respectively, totaling $60,000,000 in principal amount of the Notes in the

Filing Documents

• ef20030042_8k.htm (8-K) — 47KB
• ef20030042_ex10-1.htm (EX-10.1) — 31KB
• ef20030042_ex10-2.htm (EX-10.2) — 114KB
• 0001140361-24-027667.txt ( ) — 363KB
• imcr-20240528.xsd (EX-101.SCH) — 4KB
• imcr-20240528_lab.xml (EX-101.LAB) — 21KB
• imcr-20240528_pre.xml (EX-101.PRE) — 16KB
• ef20030042_8k_htm.xml (XML) — 4KB

01

Item 1.01. Entry into a Material Definitive Agreement. On May 28, 2024, Immunocore Holdings plc (the "Company") entered into a registration rights agreement (the "Registration Rights Agreement") with 667, L.P. and Baker Brothers Life Sciences, L.P. (collectively, the "BBA Funds"), as described below under the heading "Registration Rights Agreement" in Item 5.02 and incorporated herein by reference.

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Mr. Ranjeev Krishana On May 28, 2024, upon the nomination of the BBA Funds pursuant to a letter agreement, as modified by a waiver agreement between the Company and the BBA Funds dated February 3, 2021 and an amendment between the Company and the BBA Funds dated February 6, 2024 (the "Amendment" and referred to as amended as the "Letter Agreement") and the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors of the Company (the "Board"), the Board appointed Mr. Ranjeev Krishana to serve as a Class I director of the Company, effective May 28, 2024. Mr. Krishana will serve for a term expiring at the Company's 2025 annual meeting of shareholders, and until his successor is elected and has been qualified, or until his earlier death, resignation or removal. Mr. Krishana, age 50, has served as a partner at Baker Bros. Advisors LP. ("Baker Bros") since 2011. Prior to joining Baker Bros., from 2003 to 2007 and from 2008 to 2011, he held a series of commercial, strategy, and business development leadership roles of increasing responsibility at Pfizer, Inc., serving as an executive in their pharmaceutical business across a variety of international regions and markets, including Asia, Europe, and Latin America. Mr. Krishana initially began his career as a strategy consultant at Accenture plc. Mr. Krishana currently serves on the board of directors of BeiGene, Ltd. Mr. Krishana holds a B.A. in Economics and Political Science from Brown University, and a M.P.P. from Harvard University. Mr. Krishana will be compensated in accordance with the Company's non-employee director compensation policy as described in the Company's definitive proxy statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on April 12, 2024, including an optio

Financial Statements and Exhibits

Financial Statements and Exhibits Exhibit No. Description 10.1 Amendment No. 1 to Letter Agreement by and among the Company and 667, L.P. and Baker Brothers Life Sciences, L.P., dated February 6, 2024. 10.2 Registration Rights Agreement, dated May 28, 2024, by and among the Company and 667, L.P. and Baker Brothers Life Sciences, L.P. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Certain portions of this exhibit (indicated by asterisks) have been redacted in accordance with Regulation S-K, Item 601(b)(10).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOCORE HOLDINGS PLC Dated: May 28, 2024 By: /s/ Bahija Jallal, Ph.D. Name: Bahija Jallal, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR